AI assistant
Bionano Genomics, Inc. — Director's Dealing 2018
Aug 21, 2018
35041_dirs_2018-08-21_32c874a8-80e5-47a0-95a3-77157950b39c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: BioNano Genomics, Inc (BNGO)
CIK: 0001411690
Period of Report: 2018-08-21
Reporting Person: Cao Han PHD (Chief Scientific Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1413 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $291.04 | 2019-01-14 | Common Stock (46) | Direct | |
| Stock Option (right to buy) | $38.52 | 2020-04-01 | Common Stock (46) | Direct | |
| Stock Option (right to buy) | $42.80 | 2021-08-09 | Common Stock (2344) | Direct | |
| Stock Option (right to buy) | $64.20 | 2025-01-28 | Common Stock (1599) | Direct | |
| Stock Option (right to buy) | $64.20 | 2025-01-28 | Common Stock (2557) | Direct | |
| Stock Option (right to buy) | $1.28 | 2027-02-06 | Common Stock (51329) | Direct | |
| Series B Convertible Preferred Stock | $0.00 | Common Stock (254275) | Direct | ||
| Series C Convertible Preferred Stock | $0.00 | Common Stock (52720) | Direct | ||
| Series D Convertible Preferred Stock | $0.00 | Common Stock (4362062) | Direct | ||
| Series D-1 Convertible Preferred Stock | $0.00 | Common Stock (104167) | Direct | ||
| Series D Convertible Preferred Stock Warrant (Right to Buy) | $0.41 | 2026-03-04 | Series D Convertible Preferred Stock (10731083) | Direct |
Footnotes
F1: The shares subject to the option are fully vested and exercisable.
F2: 25% of the shares vested on January 29, 2016, and the remaining shares vest in 12 equal quarterly installments thereafter.
F3: 25% of the shares vested on February 7, 2017, and the remaining shares vest in 12 equal quarterly installments thereafter.
F4: The convertible preferred stock is convertible at any time at the holder's election and automatically converts upon the consummation of a qualified public offering of the registrant. There is no expiration date for any series of preferred stock.